An acne treatment from GlaxoSmithKline’s (NYSE:GSK) skin products subsidiary Stiefel has received recommendation for approval in Europe.

The Medicine and Healthcare products Regulatory Agency recommended approval for a new version of Duac, a topical gel that treats mild to moderate acne vulgaris in adults and adolescents. The new fixed-dose Duac contains active ingredients clindamycin, (1 percent) and benzoyl peroxide (3 percent). It’s a different version of parent product Duac, which is already approved in more than 50 countries around the world, including the United States.

With the positive regulatory recommendation, the new version of Duac is now on a path to become available in 15 European countries. The approval recommendation was based on a review of the data on quality, safety and efficacy of this new fixed-dose combination. The safety and efficacy was evaluated in a phase III study of 1,319 patients with mild to moderate acne. The study compared the new fixed-dose combination to each of the individual components, clindamycin or benzoyl peroxide, applied once daily for 12 weeks.

London-based GlaxoSmithKline maintains its U.S. headquarters in Research Triangle Park. Skin products unit Stiefel is also located in RTP.